The Scientific Business of Thomson Reuters Publishes Three Pharma Matters Reports Covering the First Quarter of 2008



    
    Quarterly Reports use Market Intelligence and Competitive Analysis from
    Thomson Reuters to Explore Various Aspects of the Pharmaceutical Pipeline

    
    LONDON and PHILADELPHIA, Aug. 18 /CNW/ -- Thomson Reuters, the world's
leading source of intelligent information for businesses and professionals,
has announced the availability of the Pharma Matters reports covering the time
period January-March 2008. Launched more than two years ago, the quarterly
Pharma Matters reports cover all aspects of the pharmaceutical pipeline,
leveraging strategic intelligence and competitive analysis from Thomson
Pharma(R), Newport Horizon Premium(TM) and the Thomson Messaging Mapping
System(SM).
    The Ones to Watch -- A Thomson Reuters quarterly review of the latest
phase changes in the pharmaceutical pipeline, this report is based on the
strategic data and analysis from Thomson Pharma, the world's leading
pharmaceutical competitive intelligence solution. In the report covering Q1
2008, the top five most promising drugs launched or receiving approval were:


    
    DRUG                    DISEASE                   COMPANY
    Intelence(TM)           HIV-1 infection           Tibotec
    

    
    Pristiq(TM)             Depression                Wyeth
    

    
    Ionsys(TM)              Acute pain                ALZA
    

    
    Arcalyst(TM)            CIAS1-associated          Regeneron
                            periodic syndromes
    

    
    Moxatag(TM)             Streptococcus             MiddleBrook
                            pyogenes-associated
                            pharyngitis, tonsillitis
    
    More analysis, as well as information on drugs entering clinical Phases
I, II and III, are available in the full report:
http://scientific.thomsonreuters.com/thomsonpharma/media/pdfs/tpqr/totw_jan-ma
rch_08.pdf
    (Due to the length of this URL, it may be necessary to copy and paste
this hyperlink into your Internet browser's URL address field. Remove the
space if one exists.)
    Movers and Shakers -- Introduced in mid-2007, this report is the newest
in the Pharma Matters series and covers the U.S. generics industry using data
and analysis from Newport Horizon Premium, the critical product targeting the
global business development system. Analysis from the Q1 2008 report includes:
    
    -- The U.S. generics market is remarkably robust but will be hit by the
       current downturn in drugs innovation, which will translate into a
       decline in off-patent drugs from 2012.
    -- 'Super Generic' companies such as Teva and Mylan now dominate the
       generics market and will be the best placed to survive any future
       downturns.
    -- During the first quarter of 2008, final approvals were issued on 134
       'A'-rated ANDAs, up from 108 the quarter before.
    -- 11 new products (four combination products and seven single active
       ingredient products) were subjected to paragraph IV challenges for the
       first time in Q1 2008, in comparison to the challenges made to seven
       new products in the last quarter of 2007.
    -- During the first quarter of 2008, the largest number of ANDA approvals
       went to US-based companies. Thirty different US-based corporations
       received a total of 59 final ANDA approvals.
    -- In the same time period, fourteen India-based companies received a
       total of 36 approvals, putting India in second place.
    
    To learn more about companies making their mark on the U.S. generics
market, click on this link to read the full report:
http://scientific.thomson.com/thomsonpharma/media/pdfs/tpqr/movers_shakers_jan
-mar08.pdf
    
    (Due to the length, copy and paste URL into browser window.)
    
    Who is Making the Biggest Splash? -- This report is a Thomson Reuters
expert review of the organizations that are helping to shape professional
opinions on drugs and therapies, using the unique insights of the Thomson
Message Mapping System. In this quarterly review of the scientific literature
on drugs and therapies, Thomson Reuters assesses the quantity and quality of
the materials published by pharmaceutical companies, research institutions and
other non-commercial bodies. The top five of the listed 15 organizations that
have made the biggest impact as the leading sources of information on medical
research from January-March 2008 are:

    
    1. Eli Lilly
    2. sanofi-aventis
    3. Novartis
    4. Bristol-Myers Squibb
    5. GlaxoSmithKline
    
    To see the complete list, as well as analysis and methodology, click to
read the full report:
http://scientific.thomsonreuters.com/thomsonpharma/media/pdfs/tpqr/making-a-sp
lash-mar2008.pdf
    
    (Due to the length, copy and paste URL into browser window.)
    
    To sign up for the Thomson Reuters Pharma Matters series of publications
visit: scientific.thomson.com/pharma/forms/matters/
    
    About Thomson Reuters
    
    Thomson Reuters is the world's leading source of intelligent information
for businesses and professionals.  We combine industry expertise with
innovative technology to deliver critical information to leading decision
makers in the financial, legal, tax and accounting, scientific, healthcare and
media markets, powered by the world's most trusted news organization. With
headquarters in New York and major operations in London and Eagan, Minnesota,
Thomson Reuters employs more than 50,000 people in 93 countries. For more
information, go to thomsonreuters.com.




For further information:

For further information: Eoin Bedford, Scientific, +44-207-433-4691,
eoin.bedford@thomsonreuters.com Web Site: http://www.thomsonreuters.com      
          http://scientific.thomson.com/pharma/forms/matters


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890